Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Ingelheim Forms Strategic Alliance With China’s Hisoar, Provides Tech And Training On Chemical Center

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Boehringer Ingelheim has forged a strategic alliance with China's Hisoar that will provide German technological know-how and training to Hisoar's new center for the production of precursor chemicals for pharmaceuticals

You may also be interested in...



Boehringer Ingelheim To Channel €100 Million Into Shanghai To Expand Production, Strengthen Quality Controls On APIs From China

SHANGHAI - Germany's Boehringer Ingelheim recently announced it would funnel a new €100 million ($ 150 million) investment into China to increase production capacity at its plant in the Shanghai Zhangjiang Hi-Tech Park and to introduce state-of-the-art quality control technology for active pharmaceutical ingredients sourced from China

Boehringer Ingelheim To Channel €100 Million Into Shanghai To Expand Production, Strengthen Quality Controls On APIs From China

SHANGHAI - Germany's Boehringer Ingelheim recently announced it would funnel a new €100 million ($ 150 million) investment into China to increase production capacity at its plant in the Shanghai Zhangjiang Hi-Tech Park and to introduce state-of-the-art quality control technology for active pharmaceutical ingredients sourced from China

Schering Sues Zhejiang Hisoar Pharmaceutical For Patent Infringement

Schering Corp. has sued three local firms in China - Zhejiang Hisoar Pharmaceutical, Zhejiang Hisoar Pharmaceutical Sales and Saniver Ltd - for patent infringement of its florfenicol antibiotics. Schering demands an immediate stop of its drug infringement and asks for RMB 500,000 in damages, on top of legal costs. Hisoar denies the charges and claims florfenicol is one of its key products. Analysts observe that many drug patent infringement lawsuits stem from the nation's low level of drug R&D. Domestic generic drugs increasingly threaten the market share of pharmaceutical MNCs' patented drugs, spurring the owners to file suits to contain their technology. Analysts observe that IP remains a sore point for local pharmaceutical industry's move toward internationalization. (Click here for more - Chinese Language)

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel